中晚期前列腺癌内分泌治疗临床分析

目的探讨内分泌治疗中晚期前列腺癌的临床疗效以及前列腺特异性抗原（PsA）在临床诊疗中的价值。方法对内分泌治疗的中晚期前列腺癌患者进行随访，并结合临床资料进行分析。结果共获访70例前列腺癌患者，其中死亡18例，获取完整随访资料者56例，96％患者临床症状得到改善，血清PSA下降治疗前（107．37±187．67）ng／mL与治疗后3月（32．25±123．52）ng／mL，t=3．57，P〈0．01；治疗前与治疗后6月（37．49±172．00）ng／mL，t=3．34，P〈0．01；治疗后3月与治疗后6月，t=-0．682，P〉0．05]。结论内分泌治疗是前列腺癌治疗的重要手段，可明显控制疾病进展，改善尿路梗阻等症状，但对于伴有下尿路梗阻的患者，是否结合经尿道前列腺电切术（TURP）进行治疗，仍然需要进一步探讨。

The clinical analysis on endocrine therapy of late prostate carcinoma

Objective To investigate the clinical effect of endocrine therapy in patients with late prostate carcinoma and the clinical value of PSA. Methods 70 patients with prostate carcinoma who underwent endocrine therapy were followed up and analyzed according to clinical data. Results 70 cases were followed up ,18/70 cases died. 56/70 cases have total clinical data. Clinical symptom in 96% patients improved, PSA decreased EBefore the treatment （107.37 ± 187.67）ng/mL vs. 3 months after treatment （32.25 ± 123.52）ng/mL, t = 3.57, P〈0.01; Before the treatment vs. 6 months after treatment （37.49±172.00）ng/mL, t = 3.34, P〈0.01 ; 3 months after treatment vs. 6 months after treatment t =-0. 682, P〉0.05]. Conclusion Endocrine therapy is an important method in the treatment of prostate carcinoma, and can control the disease and improve clinical symptom. But there are still debates that endocrine therapy combined with TURP treat low urinary tract obstruction.